Price · as of 2024-12-31
$2.71
Market cap 169.3M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $45.38 | +1,574.54% |
| Intrinsic Value(DCF) | $0.91 | -66.42% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $1.26 | -53.43% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $5.06 | $61.15 | $43.35 | $0.00 | $0.00 |
| 2011 | $6.02 | $28.83 | $0.00 | $0.00 | $43.38 |
| 2012 | $5.65 | $33.07 | $0.09 | $0.00 | |
| 2013 | $11.14 | $203.87 | $151.07 | $0.00 | $0.00 |
| 2014 | $7.43 | $53.14 | $45,683.68 | $1.06 | $0.00 |
| 2015 | $5.59 | $23.88 | $2,145.63 | $0.00 | $6.31 |
| 2016 | $4.70 | $34.20 | $0.54 | $0.00 | $49.72 |
| 2017 | $4.10 | $31.37 | |||
| 2018 | $3.43 | $1.26 | $0.00 | ||
| 2019 | $9.36 | $33.03 | |||
| 2020 | $8.90 | $1.02 | $0.00 | ||
| 2021 | $3.18 | $46.51 | $0.87 | $0.00 | $0.00 |
| 2022 | $0.74 | $25.45 | $0.62 | $0.00 | $0.00 |
| 2023 | $2.94 | $55.87 | $17,693.52 | $0.00 | $0.00 |
| 2024 | $1.66 | $45.38 | $19.29 | $0.00 | $1.26 |
AI valuation
Our deep-learning model estimates Compugen Ltd.'s (CGEN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $45.38
- Current price
- $2.71
- AI upside
- +1,574.54%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.91
-66.42% upside
Graham-Dodd
—
— upside
Graham Formula
$1.26
-53.43% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CGEN | Compugen Ltd. | $2.71 | 169.3M | +1,575% | -66% | — | -53% | -10.44 | 2.71 | 5.33 | -3.35 | — | 2.71 | 71.54% | -53.44% | -51.07% | -23.63% | 101.98% | -12.04% | 0.05 | -437.97 | 5.26 | 5.14 | 1.06 | -2381.00% | -1672.00% | -23724.00% | 33.30% | 2.46 | -338.90% | 0.00% | 0.00% | 1.87% | -3.24 | 0.98 | 1.73 | -3.76 |
| CRBP | Corbus Pharmaceuticals Ho… | $8.57 | 107.43M | — | — | — | — | -1.84 | 0.52 | — | 1.90 | — | 0.52 | 0.00% | — | — | -59.34% | 944.11% | -43.67% | 0.02 | -26.03 | 12.94 | 12.61 | 0.37 | -6431.00% | — | 1577.00% | -56.39% | -3.54 | 809.88% | 0.00% | 0.00% | 28.50% | 1.47 | 1.72 | — | -0.92 |
| CRDF | Cardiff Oncology, Inc. | $1.94 | 130.68M | +1,196% | -60% | — | +59% | -2.83 | 2.86 | 218.67 | -1.61 | — | 2.86 | -52.45% | -8256.32% | -7736.26% | -71.45% | 505.84% | -57.65% | 0.02 | — | 3.67 | 3.57 | 0.37 | -2737.00% | -1318.00% | 51.00% | -29.28% | -2.31 | 392.26% | 0.00% | 0.00% | 0.00% | -1.47 | -1.90 | 121.75 | -6.77 |
| IPHA | Innate Pharma S.A. | $1.72 | 160.74M | +2,263% | -50% | — | +2,571% | -2.98 | 16.70 | 11.69 | -2.08 | -0.52 | 16.70 | 100.00% | -408.64% | -391.97% | -162.91% | 247.94% | -34.57% | 3.51 | -91.12 | 2.60 | 2.50 | 0.75 | 57778.00% | -7568.00% | -7913.00% | -4.94% | -0.21 | 35.03% | 0.00% | 0.00% | 3.18% | -1.90 | -13.41 | 7.74 | -4.85 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| MOLN | Molecular Partners AG | $5.02 | 187.84M | +527% | -29% | — | +690% | -2.52 | 0.96 | 27.41 | 0.21 | — | 0.96 | -855.81% | -1231.73% | -1087.38% | -33.98% | 1006.36% | -30.29% | 0.02 | -2448.68 | 14.31 | 13.88 | 1.19 | -1587.00% | -2938.00% | 26.00% | -44.02% | -5.49 | 985.88% | 0.00% | 0.00% | 0.00% | 0.18 | 0.18 | -2.17 | 2.51 |
| NVCT | Nuvectis Pharma, Inc. | $8.86 | 234.72M | — | — | — | — | -7.46 | 10.71 | — | -6.00 | -39.42 | 10.71 | 0.00% | — | — | -188.03% | 250.21% | -105.10% | 0.00 | — | 2.38 | 2.38 | 1.15 | 1892.00% | — | 3072.00% | -8.12% | -1.20 | 145.27% | 0.00% | 0.00% | 6.64% | -6.00 | -10.34 | — | 2.32 |
| RANI | Rani Therapeutics Holding… | $1.37 | 100M | — | -55% | — | — | -0.79 | 22.30 | 43.21 | -0.92 | — | 22.30 | 100.00% | -5186.19% | -2920.04% | -761.66% | 7052.12% | -119.69% | 14.91 | -10.59 | 1.50 | 1.41 | -0.51 | -2105.00% | — | -3183.00% | -80.51% | -1.78 | 4730.69% | 0.00% | 0.00% | 0.00% | -0.87 | -1.30 | 45.23 | -7.58 |
| SAVA | Cassava Sciences, Inc. | $2.28 | 110.14M | — | — | — | — | -5.35 | 0.89 | — | -0.01 | — | 0.89 | 0.00% | — | — | -17.19% | -845.41% | -15.75% | 0.00 | — | 11.62 | 11.02 | 0.91 | -7759.00% | — | 4196.00% | -89.90% | -9.95 | -699.49% | 0.00% | 0.00% | 5.71% | -0.01 | -0.01 | — | 0.99 |
| TNXP | Tonix Pharmaceuticals Hol… | $13.97 | 178.65M | -2% | -63% | — | — | -0.23 | 0.21 | 2.92 | 0.86 | — | 0.21 | 23.07% | -1354.28% | -1288.25% | -106.12% | -200.34% | -81.95% | 0.04 | — | 6.50 | 5.83 | 1.26 | -9723.00% | 2994.00% | -4445.00% | -207.14% | -3.33 | -89.46% | 0.00% | 0.00% | 265.83% | 0.47 | 1.05 | -6.34 | -7.49 |
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
- CEO
- Eran Ophir
- Employees
- 74
- Beta
- 2.91
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.91 ÷ $2.71) − 1 = -66.42% (DCF, example).